<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457650</url>
  </required_header>
  <id_info>
    <org_study_id>201504002</org_study_id>
    <nct_id>NCT02457650</nct_id>
  </id_info>
  <brief_title>T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies</brief_title>
  <official_title>Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Institute for Innovation and Translational Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be&#xD;
      infused back to patients with NY-ESO-1- expressing malignancies. The patients pretreated with&#xD;
      a lymphodepleting preconditioning regimen will be monitored after infusion of anti-NY-ESO-1&#xD;
      TCR-transduced T cells for adverse events, persistence of anti-NY-ESO-1 TCR-transduced T&#xD;
      cells and treatment efficacy.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To evaluate the safety and the efficacy of anti-NY-ESO-1 TCR-transduced T cell-based&#xD;
      immunotherapy for patients with NY-ESO-1- expressing malignancies.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients older than one year of age, who have relapsed or refractory malignancies that&#xD;
      express both NY-ESO-1 and human leukocyte antigen (HLA)-A2 molecules.&#xD;
&#xD;
      Patients must have adequate organ functions.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Peripheral blood from patients will be collected for isolation of peripheral blood&#xD;
           mononuclear cells (PBMCs), which will be transduced with a lentiviral or retroviral&#xD;
           vector encoding an HLA-A2 restricted anti-NY-ESO-1 TCR gene.&#xD;
&#xD;
        -  Patients will receive a lymphodepleting preconditioning regimen to prepare their immune&#xD;
           system to accept modified T cells.&#xD;
&#xD;
        -  Patients will receive an infusion of their own modified T cells. They will remain in the&#xD;
           hospital to be monitored for adverse events until they have recovered from the&#xD;
           treatment.&#xD;
&#xD;
        -  Patients will have frequent follow-up visits to monitor the persistence of modified T&#xD;
           cells and efficacy of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances has been made to date in the treatment of patients with hematologic&#xD;
      malignancies, clinical trials targeting solid cancers have achieved limited efficacy. One&#xD;
      important reason is due to lack of ideal cancer antigens. NY-ESO-1 is expressed in various&#xD;
      types of cancers, including neuroblastoma, hepatoma, myeloma, melanoma, esophagus, prostate,&#xD;
      bladder, breast and ovarian cancers. While, in normal somatic tissues, NY-ESO-1 expression is&#xD;
      restricted to the germline cells, which lack HLA molecules and cannot present peptides&#xD;
      derived from NY-ESO-1 for recognition by T cells. Therefore, NY-ESO-1 specific T cells will&#xD;
      only recognize and kill NY-ESO-1-expressing cancer cells, but not normal cells, thus avoiding&#xD;
      induction of autoimmune reaction. With these unique features, NY-ESO-1 has been selected as&#xD;
      an attractive tumor antigen candidate for cancer immunotherapy in various clinical trials.&#xD;
&#xD;
      In this trial, autologous T cells engineered to express a T cell receptor (TCR) targeting&#xD;
      NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies after they&#xD;
      receive a lymphodepleting preconditioning regimen. The patients will be monitored after&#xD;
      infusion of anti-NY-ESO-1 TCR-transduced T cells for adverse events, persistence of&#xD;
      anti-NY-ESO-1 TCR-transduced T cells and treatment efficacy.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      To determine the safety and feasibility of the administration of anti-NY-ESO-1 TCR transduced&#xD;
      T cells in patients with HLA-A2+ NY-ESO-1-expressing malignancies.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To determine if the treatment can result in clinical regression of malignant tumors in the&#xD;
      patients.&#xD;
&#xD;
      To determine the in vivo persistency of the anti-NY-ESO-1 TCR-transduced T cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the safety and feasibility of the administration of anti-NY-ESO-1 TCR transduced T cells in patients with HLA-A2+ NY-ESO-1-expressing malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Clinical responses</measure>
    <time_frame>2 years</time_frame>
    <description>To determine if the treatment can result in clinical regression of malignant tumors in the patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Bladder Carcinoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Esophagus Carcinoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Synovial Sarcoma</condition>
  <condition>Other Metastatic Solid Cancers</condition>
  <arm_group>
    <arm_group_label>Anti-NY ESO-1 TCR-transduced T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.</description>
    <arm_group_label>Anti-NY ESO-1 TCR-transduced T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.</description>
    <arm_group_label>Anti-NY ESO-1 TCR-transduced T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-NY ESO-1 TCR-transduced T cells</intervention_name>
    <description>Modified cells will be infused IV over 30 minutes.</description>
    <arm_group_label>Anti-NY ESO-1 TCR-transduced T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               1. Must be pathology or cytology confirmed cancer patients with age of one year old&#xD;
                  and over；&#xD;
&#xD;
               2. Must be HLA-A2 positive, and cancer tissues express NY-ESO-1；&#xD;
&#xD;
               3. There is at least one measurable disease: diameter ≥20mm or spiral CT≥10mm；&#xD;
&#xD;
               4. Willing to sign a durable power of attorney；&#xD;
&#xD;
               5. Able to understand and sign the Informed Consent Document；&#xD;
&#xD;
               6. Performance status：ECOG 0-2；&#xD;
&#xD;
               7. Life expectancy：More than 3 months；&#xD;
&#xD;
               8. Patients must be willing to practice birth control for four months after&#xD;
                  receiving a lymphodepleting preconditioning regimen；&#xD;
&#xD;
               9. Patients with no pregnancy and lactation；&#xD;
&#xD;
              10. Hematopoietic： (1) Absolute neutrophil count &gt; 1000/mm3 without support of&#xD;
                  filgrastim； (2) Platelet count &gt; 100,000/mm3； (3) Hemoglobin &gt; 8.0 g/dL； (4)&#xD;
                  lymphocyte count &gt;500/mm3； (5) WBC &gt; 3,000/mm3；&#xD;
&#xD;
              11. Chemistry： (1) AST and ALT &lt; 2.5 times upper limit of normal； (2) Serum&#xD;
                  creatinine≤1.6 mg/dl； (3) Bilirubin ≤1.5 mg/dL（3.0 mg/dL in patients with&#xD;
                  Gilbert's syndrome）；&#xD;
&#xD;
              12. Seronegative for hepatitis B and C viruses；&#xD;
&#xD;
              13. Seronegative for human immunodeficiency virus (HIV) antibody；&#xD;
&#xD;
              14. More than four weeks must have elapsed since any prior systemic therapy at the&#xD;
                  time of randomization, and patients' toxicities must have recovered to a grade 1&#xD;
                  or less (except for alopecia or vitiligo). Patients may have undergone minor&#xD;
                  surgical procedures within the past 3 weeks, as long as all toxicities have&#xD;
                  recovered to grade 1 or less or as specified in the eligibility criteria；&#xD;
&#xD;
              15. Six weeks must have elapsed since any prior anti-CTLA4 antibody therapy to allow&#xD;
                  antibody levels to decline. Patients who have previously received any anti-CTLA4&#xD;
                  antibody and have documented gastrointestinal (GI) toxicity must have a normal&#xD;
                  colonoscopy with normal colonic biopsies.&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               1. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency&#xD;
                  Disease)；&#xD;
&#xD;
               2. Active systemic infections；&#xD;
&#xD;
               3. Coagulation disorders or other major medical illnesses of the cardiovascular,&#xD;
                  respiratory or immune system；&#xD;
&#xD;
               4. Concurrent use of systemic steroids；&#xD;
&#xD;
               5. History of severe immediate hypersensitivity reaction to any of the agents used&#xD;
                  in this study；&#xD;
&#xD;
               6. There are obvious dysfunctions in heart , liver，kidney and other vital organs&#xD;
&#xD;
               7. T cell lymphoma and leukemia patients；&#xD;
&#xD;
               8. HIV positive；&#xD;
&#xD;
               9. History of coronary revascularization or ischemic symptoms；&#xD;
&#xD;
              10. Documented Left Ventricular Ejection Fraction (LVEF) of less than or equal to 45&#xD;
                  percent tested in patients with: Clinically significant atrial and/or ventricular&#xD;
                  arrhythmias including but not limited to: atrial fibrillation, ventricular&#xD;
                  tachycardia, second or third degree heart block；&#xD;
&#xD;
              11. Documented forced expiratory volume 1 (FEV1) less than or equal to 60 percent&#xD;
                  predicted tested in patients with a prolonged history of cigarette smoking (20&#xD;
                  pk/yrs of smoking) or symptoms of respiratory dysfunction；&#xD;
&#xD;
              12. Bronchial lesions (probably shifted obstructive pneumonia or intracranial&#xD;
                  hemorrhage risk)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mingjun Wang, M.D., Ph.D.</last_name>
    <phone>15814723218</phone>
    <email>mingjunw429@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geng Tian, M.D., Ph.D</last_name>
    <phone>13724395569</phone>
    <email>tiangeng666@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjun Wang, M.D., Ph.D.</last_name>
      <phone>15814723218</phone>
      <email>mingjunw429@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Geng Tian, M.D., Ph.D.</last_name>
      <phone>13724395569</phone>
      <email>tiangeng666@aliyun.com</email>
    </contact_backup>
    <investigator>
      <last_name>Geng Tian, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mingjun Wang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

